A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer
- PMID: 12499095
- DOI: 10.1016/s0169-5002(02)00308-2
A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer
Abstract
With the availability of chemotherapy agents for first- and second-line treatment of advanced non-small-cell lung cancer (NSCLC), the patient population that requires subsequent chemotherapy is increasing. This retrospective analysis was performed to describe the clinical course after two standard or approved chemotherapy agents in patients with good overall performance status. Data were selected from patients with advanced NSCLC who had received third- or fourth-line chemotherapy after two prior chemotherapy regimens that included platinum and docetaxel given concurrently or sequentially. Prior regiments had failed due to discase progression within 90 days of chemotherapy, or unacceptable toxicity. Examination of over 700 patient records between January 1993 and January 2000 at one US and one European cancer centre revealed 43 patients that fulfilled the inclusion criteria. Response rates decreased with each line of treatment: first line, 20.9%; second line, 16.3%; third line, 2.3%; and fourth line, 0%. The disease control rate (response plus stable disease) also decreased dramatically from first- to fourth-line treatment, although it was higher for second-line treatment (74.4%) than for first-line treatment (62.8%). The median overall survival time from diagnosis was 16.4 months. The median overall survival time from the start of the last treatment (either third or fourth line) was 4 months. Patients with stage III disease at diagnosis had a longer overall survival from diagnosis than patients with stage IV disease (P=0.02). This review highlights the need for novel therapy approaches for patients with recurrent NSCLC who have failed second-line therapy and provides a baseline for the statistical design of such studies.
Similar articles
-
Retrospective analysis of third-line and fourth-line chemotherapy for advanced non-small-cell lung cancer.Clin Lung Cancer. 2012 Jan;13(1):39-43. doi: 10.1016/j.cllc.2011.06.008. Epub 2011 Sep 3. Clin Lung Cancer. 2012. PMID: 21890422
-
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.J Clin Oncol. 2000 Jun;18(12):2354-62. doi: 10.1200/JCO.2000.18.12.2354. J Clin Oncol. 2000. PMID: 10856094 Clinical Trial.
-
Brief report: retrospective review of efficacy of erlotinib or gefitinib compared to docetaxel as subsequent line therapy in advanced non-small cell lung cancer (NSCLC) following failure of platinum-based chemotherapy.Lung Cancer. 2008 Aug;61(2):262-5. doi: 10.1016/j.lungcan.2008.02.002. Epub 2008 Mar 20. Lung Cancer. 2008. PMID: 18358559
-
Docetaxel for previously treated non-small-cell lung cancer.Oncology (Williston Park). 2002 Jun;16(6 Suppl 6):45-51. Oncology (Williston Park). 2002. PMID: 12108897 Review.
-
Docetaxel for locally advanced or metastatic non-small-cell lung cancer. Current data and future directions as front-line therapy.Oncology (Williston Park). 2002 Jun;16(6 Suppl 6):53-62. Oncology (Williston Park). 2002. PMID: 12108898 Review.
Cited by
-
Third-line therapy for advanced non-small-cell lung cancer patients: feasible drugs for feasible patients.Med Oncol. 2011 Dec;28 Suppl 1:S605-12. doi: 10.1007/s12032-010-9753-3. Epub 2010 Nov 30. Med Oncol. 2011. PMID: 21116876
-
Elevated serum levels of TPS and CYFRA 21-1 predict poor prognosis in advanced non-small-cell lung cancer patients treated with gefitinib.Med Oncol. 2010 Sep;27(3):950-7. doi: 10.1007/s12032-009-9315-8. Epub 2009 Oct 15. Med Oncol. 2010. PMID: 19830603
-
Deciphering the Molecular Profile of Lung Cancer: New Strategies for the Early Detection and Prognostic Stratification.J Clin Med. 2019 Jan 17;8(1):108. doi: 10.3390/jcm8010108. J Clin Med. 2019. PMID: 30658453 Free PMC article. Review.
-
Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302).Br J Cancer. 2018 Mar 6;118(5):654-661. doi: 10.1038/bjc.2017.478. Epub 2018 Feb 13. Br J Cancer. 2018. PMID: 29438373 Free PMC article. Clinical Trial.
-
Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies.Oncotarget. 2016 Jun 28;7(26):40781-40791. doi: 10.18632/oncotarget.8205. Oncotarget. 2016. PMID: 27007055 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical